Abstract
Cell therapy can be numbered among the novel biologic therapeutics that will increase our ability to cure human disease in the years to come. While the general feeling is that in vivo use of ex-vivo expanded cellular products is relatively safe, the attempt at augmenting potency have increased the risk for adverse events. Future efforts are warranted to better characterize cellular products, and collect and analyze clinical trial outcomes through national databases, to identify risks connected to their in vivo use.
Aknowledgments
This work has been partly supported by grants from AIRC (Associazione Italiana Ricerca sul Cancro); MURST (Ministero dell’Università e della Ricerca Scientifica e Tecnologica); Ministero della Salute, Progetti Ricerca Oncologica n° RFPS-2006-2-340145; n° RFPS-2006-Regione Umbria.
Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.